The new generation of
Non-Invasive Prenatal Test.

From Labco one of Europes leaders in Diagnostic testing.

  • NeoBona - Header 1

Current situation

A conventional first-trimester screening only provides a statistical risk index.

New technology

neoBona detects possible chromosomal abnormalities in the future baby using one of the most advanced technology with no risk for the fetus.

Result

LABCO is a pioneer in new advances that make it possible to offer a non-invasive prenatal test on maternal blood giving accurate results in one week.

Around 1% of fetuses have some type of chromosomal abnormality. neoBona  is the new generation non-invasive prenatal test backed by the experience of LABCO, one of the European leaders in diagnostic testing.

What is neoBona?

The new generation of Non-Invasive Prenatal test

RELIABLE

Thanks to the cutting edge technology.

FAST

Results available in one week.

ACCURATE

Sensitivity higher than 99% for Downs Syndrome.

herader-embarazada-neobona_05

SAFE

Non-invasive for the fetus.

SIMPLE

A single blood test from the mother.

EXPERIENCE

A reliable and trusted pioneer and leader in diagnostics.

NeoBona - anomalias

Detects abnormalities

Detects the most frequent chromosomal abnormalities that occur during pregnancy by studying the cell-free fetal DNA present in the maternal blood.

NeoBona - tecnologa-avanzada

Incorporates advanced technology

Developed by Illumina, world leader in DNA sequencing, in close collaboration with LABCO. neoBona is a next-generation non-invasive prenatal test, incorporating what is called the “fetal fraction” which provides greater precision than other tests available on the market.

NeoBona - precisin

Accuracy of the analysis

A conventional first-trimester screening consists of an analysis and an ultrasound and only provides a statistical risk index, which is less reliable than neoBona, which is based on the actual fetal DNA providing greater confidence for parents.

NeoBona - gestacin-en

I am pregnant, is neoBona suitable for me?

  • Is available from the 10th week of gestation.
  • Can be performed in cases of assisted reproduction, including IVF through egg donation.
  • Is suitable for twins.
  • neoBona is a genetic screening test and as such, must be requested  by a clinician.

Why choose neoBona?

CONFIDENCE

neoBona offers parents confidence that chromosomal abnormalities in the fetus can be detected early during pregnancy. A non-invasive test does not carry the same risk to the mother of the future baby as amniocentesis.

PROFESSIONAL COUNSELLING

neoBona is the only prenatal test available that has the support of LABCO and their specialist team of more than 600 medical professionals and genetics experts to support your clinician. 

STATE-OF-THE-ART TECHNOLOGY

Developed by Illumina, world leader in DNA sequencing, in close collaboration with LABCO. neoBona is a next-generation non-invasive prenatal test, incorporating what is called the “fetal fraction” which provides greater precision than other tests available on the market.

FETAL FRACTION

Unlike conventional screening, neoBona measures the presence of fetal DNA in the blood sample from the mother, improving the reliability of the result.

NeoBona - feto en

NEXT GENERATION BIOINFORMATICS

It is the first test that combines the depth of sequencing, the percentage of fetal DNA and the measurement of the fragments size in a new algorithm named TSCORE which allows reliable results even at a low fetal fraction (<1%).

ACCURACY

A conventional first-trimester screening consists of an analysis and an ultrasound and only provides a statistical risk index, which is less reliable than neoBona, which is based on the actual fetal DNA providing greater confidence for parents.

SENSITIVITY

The sensitivity of conventional screening is 90%. This means that out of every 100 fetuses with Down’s Syndrome, traditional screening would not detect 10 cases. The sensitivity of neoBona is higher than 99%, meaning that it detects practically all cases of Down’s Syndrome. 

SPECIFICITY

The specificity of conventional screening is 95%.   In other words, the test delivers an average rate of 5% false positive results such that out of every 100 healthy fetuses, 5 are classified as positive and may be subjected to invasive procedures that neoBona makes it possible to reduce the number of false positives found in conventional screening to practically zero (<0.1%), thus preventing a significant number of unnecessary invasive procedures and reducing the risk of the fetus.

What types of chromosomal abnormalities does it detect?

1. Most frequent trisomies

A trisomy is caused by the presence of three copies of a chromosome instead of the regular two. neoBona detects the following trisomies:

  • Trisomy 21, or Downs Syndrome, is the most common trisomy.
  • Trisomy 18, or Edwards Syndrome, has a high incidence of miscarriage. This chromosomal abnormality has a high mortality rate.
  • Trisomy 13, or Pataus Syndrome, is related to a high incidence of miscarriage. This chromosomal abnormality has a high mortality rate.

2. Alterations in sex chromosomes

neoBona detects alterations in the number of sex chromosomes, including:

  • Turner Syndrome (45, X), the absence of an X chromosome in girls.
  • Klinefelter Syndrome (47, XXY), the presence of an extra copy of the X chromosome in boys.

If the result of neoBona is consistent with an alteration on chromosomes 21, 18, 13, X and Y, LABCO offers a free confirmation of the result by QF-PCR. To perform the test it is necessary to provide an amniotic fluid or chorionic villus sample.

Types of neoBona tests

There are three types of tests available, you can evaluate with your clinician which one is the most appropriate for you.

neoBona*

Trisomies 21, 18, and 13 + Fetal sex (optional)
Paired-end NGS technology
Fetal fraction 

neoBona Advanced

Trisomies 21, 18, and 13 + Fetal sex + Sex chromosomes (X and Y)
Paired-end NGS technology
Fetal fraction 

* Option available for twins. In this case if "Fetal sex" option is selected, the presence of Y chromosome is determined.

LABCO Quality Diagnostics

One of Europe's leaders in Diagnostics service

More than 15 years innovating in prenatal diagnosis.

Operates in 35 countries in Europe, Latin America, and Africa.

More than 400 million tests a year.

The company has a network of over 450 laboratories.

Over 600 medical professionals and genetics experts.

Detection rate

T21> 99,9%
T18> 97%
T13> 99,9%

logo-labco
logo-neobona

Request more information

* Required fields.